Ocugen (NASDAQ:OCGN) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 1,540,000 shares, a decrease of 24.9% from the January 15th total of 2,050,000 shares. Based on an average trading volume of 7,150,000 shares, the short-interest ratio is currently 0.2 days. Currently, 14.9% of the shares of the company are short sold.

Several equities analysts have issued reports on the stock. Chardan Capital assumed coverage on shares of Ocugen in a research note on Wednesday, November 27th. They issued a “buy” rating and a $2.00 price objective for the company. ValuEngine upgraded shares of Ocugen from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. Finally, HC Wainwright assumed coverage on shares of Ocugen in a research note on Friday, December 20th. They issued a “buy” rating and a $1.25 price objective for the company.

In related news, CEO Shankar Musunuri acquired 406,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $0.34 per share, for a total transaction of $138,040.00. Following the completion of the purchase, the chief executive officer now directly owns 263,000 shares of the company’s stock, valued at approximately $89,420. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Junge Zhang acquired 115,000 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was bought at an average price of $0.27 per share, with a total value of $31,050.00. Following the purchase, the director now directly owns 215,078 shares of the company’s stock, valued at $58,071.06. The disclosure for this purchase can be found here. Insiders acquired 1,196,000 shares of company stock valued at $421,790 in the last 90 days. 44.70% of the stock is currently owned by insiders.

An institutional investor recently raised its position in Ocugen stock. Virtu Financial LLC lifted its holdings in shares of Ocugen (NASDAQ:OCGN) by 2,626.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 449,011 shares of the company’s stock after buying an additional 432,541 shares during the period. Virtu Financial LLC owned approximately 2.81% of Ocugen worth $233,000 at the end of the most recent quarter. Institutional investors own 4.07% of the company’s stock.

NASDAQ OCGN traded up $0.01 during trading hours on Friday, hitting $0.57. The company had a trading volume of 1,525,136 shares, compared to its average volume of 5,834,224. Ocugen has a 1-year low of $0.23 and a 1-year high of $21.60. The stock has a market cap of $8.96 million, a P/E ratio of -0.01 and a beta of 2.65. The firm has a 50 day moving average of $0.59.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.66) earnings per share for the quarter. As a group, research analysts forecast that Ocugen will post -3.68 EPS for the current year.

Ocugen Company Profile

Ocugen, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases.

Featured Story: The risks of owning bonds

Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.